A clinical-stage biotechnology company in immunotherapy

Focused on developing and partnering therapies to control the immune system for immuno-oncology and autoimmmune diseases.

Our latest press release

Read more


OSE Immunotherapeutics Announces the Appointment of Dominique Costantini as Interim CEO Following the Departure of Alexis Peyroles


To receive OSE Immunotherapeutics’ latest news